MTHFR Gene: What Your Variant Actually Means

MTHFR Mutation vs. Common Variant: What C677T and A1298C Mean

TL;DR: MTHFR is a gene that helps your body convert folate into its active form. The two main variants — C677T and A1298C — are extremely common (in the 1000 Genomes Project, about 70% of people carry at least one copy of C677T or A1298C) and most carriers are healthy. Clinical relevance is limited to pregnancy planning (neural tube defect risk) and persistent elevated homocysteine. The wellness industry has dramatically overstated the impact of MTHFR variants.

Few genetic variants have generated as much internet noise as MTHFR. Search for it and you will find claims that MTHFR mutations cause everything from depression and infertility to cancer and autism. Entire supplement empires have been built on the back of this single gene.

The reality is far more measured. MTHFR variants are extremely common, most carriers are perfectly healthy, and the scientific evidence supports concern in only a handful of specific clinical scenarios. This article breaks down what the MTHFR gene actually does, what the two main variants mean, and when -- if ever -- you should care about your result.

What the MTHFR Gene Actually Does

The MTHFR gene encodes an enzyme that converts dietary folate into its active form (5-methylTHF), which your body uses for DNA repair, cell division, and regulation of homocysteine levels. When common variants reduce this enzyme's efficiency, homocysteine may rise — but usually only when folate intake is low.

MTHFR (methylenetetrahydrofolate reductase): A gene encoding the enzyme that converts folate (vitamin B9) into its biologically active form, 5-methylTHF. Common variants (C677T and A1298C) reduce enzyme efficiency but rarely cause disease on their own.

Homocysteine: An amino acid in the blood that is recycled into methionine with the help of folate-derived methyl groups. Elevated homocysteine is an independent cardiovascular risk marker, often manageable through adequate B-vitamin intake.

MTHFR stands for methylenetetrahydrofolate reductase. It is not an acronym you need to memorize. What matters is the job the enzyme performs.

Your body needs folate (vitamin B9) for a range of critical processes: building DNA, repairing cells, and regulating gene expression through a chemical process called methylation. But dietary folate cannot do these jobs directly. It has to be converted through a series of biochemical steps known as the folate cycle.

The MTHFR enzyme handles one specific step in this cycle: it converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-methylTHF). This product, 5-methylTHF, is the primary circulating form of folate in your blood and the form your body actually uses to donate methyl groups.

Those methyl groups are essential. They feed into the methionine cycle, where they help convert homocysteine (an amino acid) back into methionine. Methionine then becomes S-adenosylmethionine (SAMe), the universal methyl donor your body uses for hundreds of reactions, including DNA methylation, neurotransmitter synthesis, and detoxification.

So in short: MTHFR helps your body use folate effectively. When the enzyme works less efficiently, less 5-methylTHF is produced, which can lead to elevated homocysteine levels -- but only under certain conditions.

The Two Main Variants: C677T and A1298C

Two single-nucleotide polymorphisms (SNPs) in the MTHFR gene have been studied extensively.

C677T (rs1801133)

This is the more clinically significant variant. The "T" allele results in an amino acid change (alanine to valine) at position 222 of the enzyme, producing a thermolabile version that is less stable at body temperature.

• Heterozygous (CT): One copy of the T allele. Enzyme activity is reduced to roughly 65% of normal (measured in lymphocyte extracts, Frosst et al., 1995). This is very common.
• Homozygous (TT): Two copies. Enzyme activity drops to about 30% of normal (Frosst et al., 1995). This is where measurable biochemical effects become more likely.

In the 1000 Genomes Project, the CT genotype is found in about 46% of people of European descent. The TT genotype occurs in about 10-15% of Europeans, ranging from about 6% in Finland to about 24% in Tuscany. A review of population studies found TT in 20% or more of Italians and US Hispanics (Botto & Yang, 2000). In East Asian populations, TT averages about 10%, but exceeds 20% in Beijing. In populations of African descent, TT is less common (1-2%).

These are not rare mutations. They are common polymorphisms that have persisted in human populations for thousands of years.

A1298C (rs1801131)

This variant causes a glutamate-to-alanine substitution at position 429. Its effect on enzyme activity is milder than C677T.

• Heterozygous (AC): A smaller reduction in enzyme activity than in CC (van der Put et al., 1998).
• Homozygous (CC): Enzyme activity reduced to approximately 60% of normal (measured in lymphocytes, Weisberg et al., 1998).

A1298C on its own is generally not considered clinically significant. The compound heterozygous state (one copy of C677T and one copy of A1298C) has been studied, with some evidence of moderately reduced enzyme activity, but the clinical relevance remains debated.

What the Evidence Actually Says

Here is where we need to separate signal from noise. The peer-reviewed literature supports clinical relevance for MTHFR variants in a limited number of scenarios.

Where MTHFR Variants Genuinely Matter

Neural tube defects and pregnancy. This is the most well-established association. Women who are homozygous TT for C677T have a moderately increased risk of having a child with a neural tube defect (NTD), particularly when folate intake is low. A meta-analysis published in the American Journal of Epidemiology (Botto & Yang, 2000) found that maternal TT genotype was associated with roughly a twofold increase in NTD risk. This is one of the key reasons folic acid fortification of grain products was introduced in many countries -- and it worked. NTD rates dropped significantly after fortification programs began.

Elevated homocysteine. The TT genotype is associated with higher plasma homocysteine levels (Frosst et al., 1995, Nature Genetics), particularly when folate status is low (Jacques et al., 1996, Circulation). Elevated homocysteine is an independent risk factor for cardiovascular disease, though the relationship is more nuanced than once thought. Large randomized trials of homocysteine-lowering with B vitamins (HOPE-2, VITATOPS) showed modest reductions in stroke risk but no significant effect on heart attacks or overall mortality. The current consensus: elevated homocysteine is a marker worth monitoring, but MTHFR genotype alone is not a reliable predictor of cardiovascular events.

Where MTHFR Variants Probably Do Not Matter

Methotrexate response. Methotrexate is a folate antagonist used to treat rheumatoid arthritis, certain cancers, and autoimmune conditions. Because MTHFR is part of folate metabolism, it has been studied as a predictor of methotrexate side effects. One cross-sectional study of 214 rheumatoid arthritis patients linked the TT genotype to central nervous system side effects (Weisman et al., 2006). But a systematic review by the Dutch Pharmacogenetics Working Group (DPWG) found insufficient evidence for an MTHFR–methotrexate gene–drug interaction (van der Pol et al., 2024). For a broader look at how genetics influence medication response, see our pharmacogenomics guide.

Depression and anxiety. Studies have linked C677T TT to depression, but the effect is small. A 2007 meta-analysis in the American Journal of Epidemiology (Gilbody et al., 2007) found that TT carriers had modestly higher odds of unipolar depression than CC carriers (odds ratio 1.36). A difference that small between large groups says almost nothing about any one person. MTHFR status is not a useful predictor of depression risk.

Autism. Several meta-analyses have examined the MTHFR-autism link. While some show a marginal statistical association, the effect sizes are tiny and the studies are plagued by publication bias and heterogeneity. No major clinical guideline recommends MTHFR testing in the context of autism.

Chronic fatigue, fibromyalgia, and "detox" issues. There is no credible evidence that MTHFR variants cause chronic fatigue syndrome, fibromyalgia, or impaired detoxification. These claims are pervasive in wellness communities but are not supported by controlled studies.

Cancer. The relationship between MTHFR and cancer risk has been studied extensively with mixed results. Some cancers show a slightly reduced risk in TT carriers (possibly due to altered nucleotide balance favoring DNA stability), while others show a slight increase. The effects are small and inconsistent across populations. MTHFR genotype is not used in any standard cancer screening or risk assessment protocol.

The Methylation Myth Industry

Let us be direct: a significant wellness industry has grown around MTHFR, and much of it is not grounded in evidence.

The typical narrative goes something like this: "You have an MTHFR mutation, so your methylation is broken. This is causing your fatigue, brain fog, anxiety, and hormonal issues. You need methylfolate, methylcobalamin, SAMe, and a dozen other supplements to fix your methylation."

This framing has several problems.

First, having a common variant is not the same as having a "broken" gene. About 40% of people worldwide carry at least one copy of the C677T T allele. If this variant truly caused the cascade of symptoms attributed to it, we would expect to see clear, large-scale epidemiological signals. We do not.

Second, methylation is not a single on/off switch. It is a vast network of biochemical reactions influenced by hundreds of genes, dietary factors, and environmental inputs. Reducing it to one SNP in one gene is a dramatic oversimplification.

Third, the supplement recommendations are often untested. While methylfolate (5-methylTHF) is a legitimate and bioavailable form of folate, the elaborate supplement stacks marketed to "MTHFR mutants" have not been validated in clinical trials. Some of these products are expensive and unnecessary for the vast majority of carriers.

The American College of Medical Genetics (ACMG) issued a practice guideline in 2013 stating that MTHFR testing should not be ordered as part of a clinical evaluation for thrombophilia or recurrent pregnancy loss, because the results rarely change clinical management.

Practical Advice: What Should You Actually Do?

If you have learned that you carry one or two copies of the C677T or A1298C variant -- perhaps through a consumer genetics test -- here is what the evidence supports.

Folate Intake Matters More Than Your Genotype

Whether or not you carry an MTHFR variant, adequate folate intake is important for everyone. The recommended daily intake for adults is 400 micrograms of dietary folate equivalents (DFE), increasing to 600 mcg during pregnancy.

Good dietary sources of folate include:

• Dark leafy greens: spinach, kale, collard greens, romaine lettuce
• Legumes: lentils, chickpeas, black beans, kidney beans
• Asparagus and broccoli
• Citrus fruits and avocado
• Fortified grains (in countries with mandatory fortification)

Methylfolate vs. Folic Acid

Folic acid is the synthetic form of folate used in supplements and food fortification. It must be converted through multiple enzymatic steps -- including the MTHFR step -- to become active 5-methylTHF.

Methylfolate (also called L-5-MTHF or L-methylfolate) is the already-converted, bioactive form. It bypasses the MTHFR enzyme entirely.

There is no good evidence that people with the TT genotype need methylfolate rather than folic acid. TT homozygotes can still use folic acid, just less efficiently. Folic acid supplementation has been shown to lower homocysteine levels even in TT carriers when given at adequate doses (Ashfield-Watt et al., 2002, American Journal of Clinical Nutrition).

There is no need to avoid folic acid entirely. But if you prefer or your clinician recommends it, methylfolate is a well-tolerated alternative.

B12 and B6

Vitamins B12 and B6 are also involved in homocysteine metabolism. Ensuring adequate intake of all three B vitamins (folate, B12, B6) is more important than obsessing over a single gene variant.

When to Talk to Your Doctor

MTHFR testing is not recommended as a routine screening test. However, consider discussing your MTHFR status with your healthcare provider if:

• You are planning a pregnancy and want to optimize your folate strategy, particularly if you have a personal or family history of neural tube defects.
• You have persistently elevated homocysteine levels that are not explained by other factors (B12 deficiency, kidney disease, hypothyroidism).
• You have a history of recurrent pregnancy loss, though current guidelines note that MTHFR testing alone is unlikely to change management.

For most other scenarios, knowing your MTHFR status is informative but not actionable in a way that requires medical intervention.

If you have raw data from a consumer genetics service and want to explore your results, our guide to using raw genetic data walks through how to access and interpret your files. And if you are considering which testing service to use, we have compared the best options available in Europe in 2026.

What a Useful MTHFR Result Looks Like

One of the challenges with genetic results is that they are often presented as raw genotypes -- "rs1801133: AG" -- without context about what the letters mean or whether you should care. (In a 23andMe raw file, C677T appears as G or A instead of C or T, because the file reads the other DNA strand. AG in that file means the CT heterozygote described above.)

A useful result goes further: what the specific genotype means for enzyme function, how common it is in the relevant population, and what -- if anything -- the evidence suggests considering. If you are building a tool that does this, GET https://deepdna.ai/api/v1/variants/rs1801133 returns C677T with its alleles, effect and sources, free and without a key.

A good result does not tell anyone their methylation is "broken", and it does not come with a supplement stack. It is a clear, referenced summary that a person can bring to their doctor or simply read out of curiosity.

Because understanding your genetics should not require a biochemistry degree -- but it should be honest. For a broader look at how genetic testing identifies variants like MTHFR, see our explainer on how DNA testing works. And for the full picture of what modern DNA analysis can reveal, start with our complete guide to DNA analysis.

Frequently Asked Questions

Is MTHFR a serious genetic mutation?

No. MTHFR C677T and A1298C are common polymorphisms, not rare mutations. About 40% of people worldwide carry at least one copy of the C677T T allele. Most carriers experience no health issues, and the variants are clinically significant only in specific contexts like pregnancy planning or persistently elevated homocysteine.

Should I take methylfolate if I have an MTHFR variant?

There is no good evidence that people who are homozygous TT for C677T need methylfolate rather than folic acid. TT carriers can still use folic acid, just less efficiently. Adequate folate intake from any source is more important than the specific supplement form.

Does MTHFR cause depression or anxiety?

Not in any way that helps an individual. A 2007 meta-analysis found a small association between the C677T TT genotype and depression (odds ratio 1.36), but an effect that size does not predict who will become depressed. MTHFR status is not a useful predictor of depression risk.

How do I find out my MTHFR status?

You can check your MTHFR status by looking up rs1801133 (C677T) and rs1801131 (A1298C) in your raw data file from 23andMe, AncestryDNA, or a similar service. See our MTHFR gene reference page for a concise variant lookup and primary-source citations.

Key Takeaways

• MTHFR is one of the most common genetic variants in the world. Carrying it does not mean something is wrong with you.
• The enzyme converts folate into its active form. Reduced activity can lead to higher homocysteine, but usually only when folate intake is low.
• Clinical relevance is limited to pregnancy planning (neural tube defect risk) and persistent hyperhomocysteinemia. For methotrexate, the DPWG found insufficient evidence for an MTHFR interaction.
• The wellness industry has dramatically overstated the impact of MTHFR variants. Most claims about MTHFR causing chronic disease are not supported by rigorous evidence.
• Adequate folate intake from diet or supplements (methylfolate or folic acid) is the most practical step, regardless of genotype.
• Talk to your doctor if you are pregnant or planning to become pregnant, or have confirmed elevated homocysteine.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making decisions based on genetic test results.

This article was created with AI assistance and reviewed by the DeepDNA editorial team.